Former POINT Biopharma CEO, Joe McCann, Joins TAG1 Board of Directors to Advance Isotope Access in Radiopharmaceuticals

ST. LOUIS, May 20, 2025 /PRNewswire/ -- TAG1 Inc., a premier supplier of clinical quantities of medical isotopes, today announced the appointment of Joe McCann to its Board of Directors. A highly respected figure in the radiopharmaceutical industry, McCann brings decades of leadership in manufacturing, operational strategy, and company building.

McCann, who previously served as CEO of POINT Biopharma and has led multiple companies through growth, clinical development, and acquisition, is widely recognized for his deep expertise in radiopharmaceutical manufacturing and supply chain operations. He is currently an active investor, board member, and advisor to emerging biotech companies focused on precision medicine.

"What drew me to radiopharma was how close the work is to the patient, you feel the impact of every decision. Whether it's a manufacturing delay or a supply chain failure, there are real people affected on the other end. TAG1 understands this deeply," said McCann. "Their approach to isotope production reflects the kind of near-perfect execution this field demands. I'm excited to support the team as they build solutions that could transform both access and outcomes."

Lead-212 is vital to TATs, but its development has been limited by supply and infrastructure challenges, issues TAG1 aims to solve. McCann's appointment supports the company's focus on scaling its generator and strengthening its operational foundation.

"Joe understands the technical rigor it takes to succeed in radiopharma," said Sumit Verma, CEO and Founder of TAG1, Inc. "He has built and led organizations through the extreme demands of the radiopharma industry, always with a deep sense of responsibility and precision. His track record in building high-performing teams make him a tremendous asset as we work to build a reliable, patient-focused supply chain for Lead-212."

McCann joins a growing group of board members helping to position TAG1 as a reliable supplier of high-purity medical isotopes. TAG1's proprietary generator is designed to decentralize Lead-212 production and deliver consistent, on-demand access to radiopharmacies, hospitals, and research centers.

"We're excited to welcome such a visionary leader to TAG1's Board," said Dimitrios Mantzilas, CTO of Precirix and TAG1 Board Member. "Joe's understanding of the industry is second to none. He brings a clarity of purpose that is rare and urgently needed in our field, especially as alpha therapies scale. His experience will be invaluable as we move from development into sustained delivery."

About TAG1 Inc.
TAG1 Inc. is a leading supplier of medical isotopes, specializing in the production of Lead-212 (Pb-212) for use in Targeted Alpha Therapies (TATs). The TAG1 Generator is a proprietary and innovative generator designed to unlock the supply of Pb-212 for pre-clinical and clinical trials of targeted alpha therapies utilizing this vital radioisotope. With a mission to improve cancer treatment through innovative nuclear medicine, TAG1 Inc. is dedicated to advancing the radiopharmaceutical supply chain and supporting the development of groundbreaking therapies. Learn more at www.tag1inc.com.

SOURCE TAG1, Inc.